<DOC>
	<DOCNO>NCT03074032</DOCNO>
	<brief_summary>This PhaseI , open-label study , Dose-Escalation Study , tolerate dos escalate next dos safety , tolerability , PK evaluate metastatic castration-resistant prostate cancer ( mCRPC ) patient . Tumor assessment PSA value evaluate study additional point .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics ONC1-0013B Patients With Progressive Metastatic Castration-resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Men age 18 year old . 2 . Histologically confirm diagnosis prostate cancer 3 . Castrate level testosterone blood serum &lt; 1,7 nmol/l &lt; 50 ng/dl 4 . PSA level screen &gt; 2 ng/ml 5 . Progression metastatic CRPC chemical castration gonadotropinreleasing hormone ( GnRH ) analogue chemical castration subsequent chemotherapy . 6 . The patient 's ECOG performance status 0 2 7 . Patients previously treat docetaxel chemotherapy receive 2 less prior line chemotherapy mCRPC 8 . The expected survival time le 12 week 1 . Prior anticancer therapy : Treatment chemotherapeutic agent radiotherapy within 4 week prior screen preserve toxicity â‰¥ II grade accord CTCAE scale , related prior anticancer therapy ( exclude alopecia ) Prior antiandrogen therapy : flutamide within 4 week prior screen bicalutamide within 6 week prior screen Exposure bisphosphonates allow treatment start prior screen 2 . Clinically significant cardiovascular system disease : 3 . Clinically significant central nervous system disease : 4 . History significant concomitant disease , Investigator 's opinion , may cause disease recurrence ( i.e . uncontrolled diabetes mellitus ) 5 . Prior concomitant therapy : Exposure drug may cause convulsive state within 4 week prior screen Exposure treatment characteristic CYP3A4 CYP2D6 inhibitor within 4 week prior screen Exposure treatment relate Class I risk QTinterval prolongation ; exposure treatment relate Class II risk QTinterval prolongation allow patient receive less 5 halflife period flatdosed treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>